HomeCompareSFNXF vs MRK

SFNXF vs MRK: Dividend Comparison 2026

SFNXF yields 1.59% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.7K in total portfolio value
10 years
SFNXF
SFNXF
● Live price
1.59%
Share price
$246.92
Annual div
$3.94
5Y div CAGR
0.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.1K
Annual income
$190.14
Full SFNXF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SFNXF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSFNXFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SFNXF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SFNXF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SFNXF
Annual income on $10K today (after 15% tax)
$135.49/yr
After 10yr DRIP, annual income (after tax)
$161.62/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,166.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SFNXF + MRK for your $10,000?

SFNXF: 50%MRK: 50%
100% MRK50/50100% SFNXF
Portfolio after 10yr
$39.4K
Annual income
$4,994.14/yr
Blended yield
12.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SFNXF
No analyst data
Altman Z
4.1
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SFNXF buys
0
MRK buys
0
No recent congressional trades found for SFNXF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSFNXFMRK
Forward yield1.59%2.76%
Annual dividend / share$3.94$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.7%32.7%
Portfolio after 10y$22.1K$56.8K
Annual income after 10y$190.14$9,798.13
Total dividends collected$1.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SFNXF vs MRK ($10,000, DRIP)

YearSFNXF PortfolioSFNXF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,861$160.52$11,206$366.19$345.00MRK
2$11,785$164.07$12,650$502.35$865.00MRK
3$12,777$167.55$14,407$694.19$1.6KMRK
4$13,843$170.96$16,585$967.82$2.7KMRK
5$14,986$174.31$19,342$1,363.89$4.4KMRK
6$16,213$177.60$22,913$1,947.19$6.7KMRK
7$17,528$180.82$27,662$2,823.89$10.1KMRK
8$18,939$183.99$34,159$4,173.35$15.2KMRK
9$20,452$187.09$43,337$6,308.80$22.9KMRK
10$22,074$190.14$56,776$9,798.13$34.7KMRK

SFNXF vs MRK: Complete Analysis 2026

SFNXFStock

Sofina Société Anonyme is a private equity and venture capital firm specializing in direct and fund of funds investments. Within direct investments, it specializes in growth capital, early, startup, later stages, mature, emerging growth, mid venture, late venture, industry consolidation, and LBO investments. The firm primarily invests in portfolio of companies that engages in digital transformation, consumer & retail, education, healthcare, energy and services, e-commerce, consumer goods, digital, satellite operations, industry, finance companies, and financial services worldwide. It also invests in the media, communications, insurance, property development sectors. The firm typically invests in European based companies with a global exposure, and it also has a particular focus on companies based in Western Europe and Asia such as in India, China and South East Asia and also in the United States. It invests between €75 million ($84.81 million) and €300 million ($339.2 million) in companies with an enterprise value between €250 million ($282.7 million) and €4500 million ($5088.41 million) in minority investments, and €15 million ($16.96 million) and €50 million ($56.54 million) in companies operating in emerging markets or fast growing sectors. It invests in privately owned and listed companies. It invests in private companies to support growth, finance acquisitions, give liquidity to existing shareholders/families, support sales processes, and make minority investment alongside shareholders controlling shareholders and in listed companies for replacement of existing shareholder, long term support of controlling shareholders, and delisting. Within fund of funds, the firm focuses on private equity, venture capital and growth equity funds, and selected relationships in buyout and special situations. It also manages funds in the fields of private equity and hedge funds. It typically invests in the US, Europe and Asia, and also concentrates on emerging markets. The firm makes between €10 million ($11.31 million) and €40 million ($45.23 million) commitments in funds. The firm prefers to hold a minority ownership equity in its portfolio companies and also seeks board seat. The firm also prefers majority stake and co-invests. It typically holds its investments for ten to twelve years. Sofina Société Anonyme was founded in 1980 and is based in Brussels, Belgium with additional offices in Luxembourg and Singapore.

Full SFNXF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SFNXF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SFNXF vs SCHDSFNXF vs JEPISFNXF vs OSFNXF vs KOSFNXF vs MAINSFNXF vs JNJSFNXF vs ABBVSFNXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.